abcam discoveries

>

SEE WHAT ABCAM CAN DO FOR YOUR LAB?

Over the last 15 years, Abcam has remained committed to supporting scientists on their quest for discovery. We’ve focused on continually improving our high quality products and services by improving our global delivery times, enhancing our customer service offering, and increasing the validation information of our products. We’ve also expanded our product range beyond primary antibodies to include secondaries, proteins and peptides, lysates, biochemicals, immunoassays and other kits.

Affinium

Affinium is a specialty pharmaceutical company developing a new class of antibiotics that targets FabI in the bacterial fatty acid synthesis pathway AFN-1252, the lead clinical compound, is a first-in-class antibiotic for both oral and IV treatment of staphylococcal infections. AFN 1252 has highly potent activity only against staphylococci, including MRSA and all other drug resistant strains, and therefore may protect from off-target, negative effeccts of broader spectrum agents.

Zyoxel

Zyoxel develops and supplies cell culture platforms that support more physiologically relevant tissue models for pharmaceutical drug discovery applications:

• Enabling the study of cellular behaviour and function in a more in vivo-like environment
• Providing responses which closely replicate human clinical responses
• Reducing the use of animals in testing
• Reducing late stage clinical trial failures by identifying unsafe drugs and through selection of the most efficacious candidates earlier in development
• Enabling more cost efficient drug development meaning that new medicines can be bought to market more quickly

Liver Chip enables cell culture in a 3D perfused state for advanced toxicity and efficacy testing

CYP Design

De Montfort University (DMU) has joined forces with Ithaka Life Sciences to market new technology invented by Prof Bob Chaudhuri, which will provide new products and services based on a set of proteins, named cytochrome P450s (CYPs). CYPs are found in the human liver and are mostly responsible for the metabolism of drugs in people. These proteins are commercially available for use by firms involved in the discovery of new drugs, but are inconvenient to use as they must be transported and stored at temperatures as low as minus 80 degrees Celsius.
The new technology from DMU allows CYPs to be shipped and handled at room temperature, eliminating the need for a cold chain. This will reduce the cost and make their use in testing new drugs much quicker and easier.
DMU and Ithaka have established a new company called CYP Design Ltd (CDL). DMU has licensed the new technology to CDL which will now bring the new products to market. Ithaka has worked closely with Prof Chaudhuri to set up CDL and is leading the implementation of the business strategy through Dr Bill Primrose as CEO and Dr Paul Rodgers as chairman.

http://www.cyp-design.com/

KERACOL

Keracol  ‘functional, natural, sustainable cosmetics’,  is a spin-out company from the University of Leeds, producing cosmetic products for hair coloration, hair care and skin care using novel approaches to the extraction, fractionation and purification of natural active molecules in the cleanest, most energy efficient way.
The company was founded by Dr Richard Blackburn, Senior Lecturer in Coloration Technology, and Prof Christopher Rayner, Head of Organic Chemistry, at the University of Leeds. Prof Rayner previously founded C-Capture, and he and Dr Blackburn together founded DyeCat, both spinouts from Leeds.

Keracol Leeds healthcare products & services 16-Aug-11 http://www.keracol.co.uk

Qvella

Canadian biotech company Qvella, headquartered in Toronto, is a molecular diagnostics company with new detection technology – preparing to bring a solution to the question of whether, and what, to prescribe when treating a possible infection is a problem.

If antibiotics are needed, they are most effective if used promptly – but the price of giving unnecessary treatment can be high, and includes not only the cost of the drugs themselves but also the growth of resistant strains of bacteria.

Currently, doctors can only get a definitive answer as to whether a patient is infected, and with what type of bacteria, after a sample from the patient is cultured in a lab, a process that takes between 24 and 72 hours. When a patient is in crisis, waiting that long simply isn’t an option. Sepsis, sometimes called a blood infection, is one such serious condition. It is the second cause of death among critical patients.

http://business.financialpost.com/2012/05/22/new-device-to-help-healthcare-workers-avoid-unnecessary-treatment/

https://www.htx.ca/Investment.aspx

Encycle Therapeutics

MaRS Innovation and CQDM had jointly collaborated to form Encycle Therapeutics, a startup that was created around disruptive technology, developed by Prof Andrei Yudin of the University of Toronto, involving the cyclization of biologically active peptides. A year later, I’m pleased to report that Encycle is alive and kicking. The company has since recruited seasoned management, and its developing product line is drawing tremendous interest from global pharmaceutical groups.

http://marsinnovation.com/

PERFUSIX

PERFUSIX is the world’s first and only commercial provider of ex-vivo organ perfusion services. PERFUSIX employs clinically proven ex-vivo organ perfusion technology and processes that restore and improve the function of donor organs. Most importantly, PERFUSIX increases the number of organs available for transplant, improves patient and organ survival, improves recipient quality of life, and reduces post-transplant care costs.

http://www.perfusix.com/

TearLab Osmolarity System

TearLab (NASDAQ:TEAR; TSX:TLB) has reported third quarter net revenues of $1.2-million, an increase of 264% from $333,000 for the same period in 2011, and up 69% sequentially from $716,000 in the second quarter this year.

TearLab Osmolarity System

Growing doctor interest in our technology and the significant role that it can play in the objective diagnoses and management of dry eye disease drove our strong revenue performance in what is historically a seasonally weaker third quarter in the eye care industry. A total of 92 orders for TearLab systems were booked in the period.  Of those, 77 were through the company’s access programs, 6 were direct purchases and 9 were purchased outside of the U.S.

Oxford Performance Materials

Oxford Performance Materials  OsteoFab^TM Medical Devices and ImplantsReceives FDA approval.

Breaking the mold for the medical device market.

Utilizing the most advanced materials and technology, our OsteoFab^TM process can reproduce exactly what you design, or exactly what nature intended by “printing” medical implants derived directly from a CT Scan or MRI file for a perfect anatomical fit with our own OXPEKK®-IG polymers.

However, this technology allows us to go beyond merely replicating shapes: we also have the ability to meet specific performance requirements as anatomically applicable. Through our proprietary “Coherent Implantology Process”, fit, form and bio-function are digitally calculated, constructed, and then produced. http://www.oxfordpm.com/biomedical_parts.html

DLVR Therapeutics Inc

DLVR’s innovative technology is based on the synthesis and use of an HDL-mimetic phospholipid-based nanoparticle called HPPS (HDL-like Peptide-Phospholipid Scaffold).

DLVR Therapeutics Inc. is based in Toronto. Co-founded by University Health Network, the Ontario Institute for Cancer Research and MaRS Innovation, the Company is developing an innovative, HDL-like Peptide-Phospholipid Scaffold (HPPS) nanoparticle delivery system. HPPS enhances cell targeting and bypasses endosomal degradation, two common problems which beset contemporary delivery systems. Mechanistically, HPPS appropriates HDL’s affinity for its natural ligand, Scavenger Receptor B1 (SR-B1) to preferentially target this receptor.  Upregulated in many solid tumors such as breast, colorectal, pancreatic and ovarian, SR-B1 facilitates direct delivery of payload to the cytosol of tumor cells. The ultra-small HPPS particle is suitable for a variety of different RNAi payloads. The company’s development strategy is to collaborate with partners that have developed novel RNAi therapeutics that require an innovative delivery technology.

http://dlvrtherapeutics.ca/company-info/

Read More

NPS pharma

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) is a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide.

The company’s lead product, Gattex® 0.05 mg/kg/d (Teduglutide [rDNA origin]) for Injection for subcutaneous use is FDA-approved for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. NPS is also developing Natpara® (rhPTH[1-84]) for the treatment of adult hypoparathyroidism and expects to submit its Biologic License Application (BLA) to the FDA in mid-2013. NPS’s earlier stage pipeline includes two calcilytic compounds, NPSP790 and NPSP795, with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia with hypercalciuria (ADHH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates.

OXehealth

Oxehealth, spun out from Oxford’s Institute of Biomedical Engineering, will allow patient’s health to be monitored using a webcam and a software application.

The software will detect a patient’s heart rate, respiratory rate and oxygen saturation even in artificial light without the need for any physical contact or additional hardware.

http://www.oxehealth.com/